Published in Br J Cancer on January 08, 2008
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. Br J Cancer (2012) 1.01
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Br J Cancer (2013) 1.01
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer (2011) 0.91
High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Transl Med (2011) 0.91
ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting. Ann Coloproctol (2015) 0.85
Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol (2014) 0.84
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer Chemother Pharmacol (2009) 0.84
Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. J Natl Cancer Inst (2015) 0.84
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. J Cancer Res Clin Oncol (2009) 0.80
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. J Cancer (2015) 0.75
First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. Onco Targets Ther (2009) 0.75
Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clin Exp Metastasis (2012) 0.75
Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. World J Gastroenterol (2016) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem (1974) 27.82
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Epidermal growth factor. J Biol Chem (1990) 4.79
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol (2005) 2.16
Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther (2002) 2.13
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev (1998) 2.11
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res (2002) 1.78
In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res (1993) 1.37
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer (2003) 1.34
Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs (2005) 1.31
Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol (2000) 1.31
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol (2005) 1.24
Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer (2002) 1.20
Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res (2004) 1.08
Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat (2004) 1.07
Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol (2003) 0.95
Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology (2002) 0.91
Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Int J Mol Med (1998) 0.82
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst (1995) 3.00
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res (1998) 2.63
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol (2009) 1.92
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol (2002) 1.61
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol (1998) 1.53
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol (2004) 1.51
Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer (1992) 1.45
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci U S A (2002) 1.38
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study. Radiother Oncol (1997) 1.38
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol (1992) 1.37
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer (2003) 1.34
A 'DNA replication' signature of progression and negative outcome in colorectal cancer. Oncogene (2009) 1.33
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol (1995) 1.32
The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways. Oncogene (2009) 1.30
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A (1998) 1.24
Morphological analyses of paraspinal muscles: comparison of progressive lumbar kyphosis (camptocormia) and narrowing of lumbar canal by disc protrusions. Neuromuscul Disord (1994) 1.20
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A (2000) 1.19
Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett (1998) 1.15
Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene (2001) 1.15
Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst (1993) 1.14
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer (2008) 1.13
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer (2003) 1.12
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol (1998) 1.10
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer (1999) 1.09
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res (1997) 1.08
Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris (2001) 1.08
In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther (2007) 1.06
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol (2010) 1.05
Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer (1997) 1.04
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol (1998) 1.04
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1996) 1.02
DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients. Oncogenesis (2012) 1.00
CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer (1995) 0.99
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res (1994) 0.99
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer (2007) 0.98
Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther (2000) 0.98
Gastric mucosal lesions produced by intravenous infusion of aspirin in cats. Gastroenterology (1976) 0.98
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol (1997) 0.97
Adaptation to DNA damage and stimulation of genetic instability: the double-edged sword mammalian DNA polymerase kappa. Biochimie (2005) 0.96
Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen. Am J Pathol (1993) 0.96
Overexpression of DNA polymerase beta: a genomic instability enhancer process. FASEB J (1999) 0.96
Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer (1998) 0.95
Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer. Oncogene (2006) 0.95
Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death Dis (2013) 0.95
Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res (1994) 0.95
A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol (1999) 0.95
Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression. Int J Cancer (1994) 0.94
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron (1994) 0.94
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer (1997) 0.94
Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene (1999) 0.93
[Genetic factors as determinants of the waking-sleep cycle in the mouse (author's transl)]. Brain Res (1974) 0.93
Nucleotide excision repair DNA synthesis by excess DNA polymerase beta: a potential source of genetic instability in cancer cells. FASEB J (2000) 0.93
New mutations in and around the L2 disordered loop of the RecA protein modulate recombination and/or coprotease activity. J Bacteriol (1992) 0.93
Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta. Oncogene (2008) 0.92
RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucleic Acids Res (2001) 0.92
Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol Pharmacol (2005) 0.91
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol (2005) 0.90
Antitumor activity of 2',3'-dideoxycytidine nucleotide analog against tumors up-regulating DNA polymerase beta. Mol Pharmacol (2001) 0.89
Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos (1998) 0.89
[Primary dural lymphoma: a report of two cases with review of the literature]. Rev Neurol (Paris) (2003) 0.89
Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal. Nephron (1989) 0.89
Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol (1998) 0.89
Carcinocythemia as the single extension of breast cancer: report of a case and review of the literature. Ann Oncol (2001) 0.88
Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol (1993) 0.88
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer (1992) 0.88
The equine herpes virus 4 thymidine kinase is a better suicide gene than the human herpes virus 1 thymidine kinase. Gene Ther (1999) 0.88
CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol (1996) 0.88
[Adverse effects of anticancer drugs: apropos of a pharmacovigilance study at a specialized oncology institution]. Therapie (2001) 0.87
Genetic studies of sleep in mice. Nature (1972) 0.86
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. Br J Cancer (2007) 0.86
Proteomic analysis of RCL2 paraffin-embedded tissues. J Cell Mol Med (2008) 0.86
Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer (2011) 0.85
Effects of a single intrastrand d(GpG) platinum adduct on the strand separating activity of the Escherichia coli proteins RecB and RecA. FEBS Lett (1993) 0.85
Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice. Br J Cancer (1993) 0.85
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol (1990) 0.85
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer (2005) 0.85
Intraoperative testosterone assay for virilizing ovarian tumor topographic assessment: report of a Leydig cell tumor of the ovary in a premenopausal woman with an adrenal incidentaloma. J Clin Endocrinol Metab (2002) 0.84
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol (2007) 0.84